Clinical Trial Update: Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) [Phase 1]

View source ↗

Summary

Phase 1 study of belimumab in systemic lupus erythematosus has completed. The trial reported early safety, tolerability, and pharmacokinetic data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Belimumab (Benlysta) (belimumab)

Snippet

Sponsor: Human Genome Sciences Inc. | Conditions: Systemic Lupus Erythematosus | Phase 1 | Status: COMPLETED